News - Pharmaceuticals
PBS adds first ustekinumab and omalizumab biosimilars in inflammatory and allergic conditions
From 1 August 2025, two new biosimilars – SteQeyma (ustekinumab) and Omlyclo (omalizumab) – have been listed on the Pharmaceutical […]
MoreNews - Pharmaceuticals
November PBAC agenda unveiled amid tensions over tariff risks
The Department of Health has unveiled the agenda for the November 2025 meeting of the Pharmaceutical Benefits Advisory Committee (PBAC), […]
MoreNews - Pharmaceuticals
Specialist colleges launch unified advocacy agenda
Specialist medical colleges are dismantling old governance walls and building a united front to tackle the nation’s healthcare crisis head-on, […]
MoreNews - Pharmaceuticals
Medicines Australia and Research Australia weight in on key productivity pillars: Economic reform roundtable
Medicines Australia and Research Australia have made strong cases to the Treasury’s Economic Reform Roundtable, calling for national reforms and […]
MoreNews - Pharmaceuticals
Aussie-led prostate cancer trial combines world-first biomarker with novel drug duo
The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP), Ramsay Hospital Research Foundation and Bayer have joined […]
MoreNews - Pharmaceuticals
Australia’s immunisation strategy faces its toughest test yet
In an ecosystem still adjusting to the aftershocks of the COVID-19 pandemic, the future of vaccination in Australia is under […]
MoreNews - Pharmaceuticals
World-first count redefines role of IVF
A world-first estimate shows assisted reproductive technology (ART) is now part of everyday life for millions of families across the […]
MoreNews - Pharmaceuticals
Rethinking Australia’s hepatitis strategy: World Hepatitis Day
Coinciding with World Hepatitis Day, a new analysis by Hepatitis Australia reveals the face of hepatitis in Australia is changing […]
MoreNews - Pharmaceuticals
First clinical consensus takes shape on obesity drugs and cardiovascular disease
Leading health experts gathered in Melbourne yesterday for the inaugural National Stakeholder Forum on Obesity and Cardiovascular Disease to develop […]
MoreNews - Pharmaceuticals
Sanofi’s billion-dollar clampdown: Largest Aussie university deal sets gold standard in research translation
In a landmark deal for Australian research commercialisation, Sanofi has inked a US$1.15 billion agreement to acquire Vicebio, a biotech […]
MoreRecent Posts in Pharma, MedTech & Biotech
Philips remote monitoring cuts hospital costs and ICU time by 69%
August 1, 2025
in News - MedTech & Diagnostics
VB Spine breaks ground in ANZ, Takes over Stryker’s spinal implants business
August 1, 2025
in News - MedTech & Diagnostics
New therapy PBS listed in advanced Parkinson’s disease
August 1, 2025
in News - Pharmaceuticals
PBS adds first ustekinumab and omalizumab biosimilars in inflammatory and allergic conditions
August 1, 2025
in News - Pharmaceuticals
November PBAC agenda unveiled amid tensions over tariff risks
July 31, 2025
in News - Pharmaceuticals
Promises, pitfalls and pressure points: Stakeholders weigh in on government’s AI healthcare report
July 31, 2025
in News - MedTech & Diagnostics
MSAC to consider funding for first TGA-approved TTVR device
July 31, 2025
in News - MedTech & Diagnostics
The triple squeeze on leaders and a messy middle: New future of work report
July 30, 2025
in Leadership & Management
Follow Us
Partner with us
News - MedTech & Diagnostics
Philips remote monitoring cuts hospital costs and ICU time by 69%
An innovative remote patient monitoring model has significantly improved post-operative care for patients, cutting ICU hours by 69% and saving […]
MoreNews - MedTech & Diagnostics
VB Spine breaks ground in ANZ, Takes over Stryker’s spinal implants business
VB Spine has officially taken the reins of Stryker’s spinal implants business in Australia and New Zealand. The transition builds […]
MoreNews - Pharmaceuticals
New therapy PBS listed in advanced Parkinson’s disease
A new therapeutic option for advanced Parkinson’s disease, Vyalev (foslevodopa with foscarbidopa), is now listed on the Pharmaceutical Benefits Scheme […]
MoreNews - Pharmaceuticals
PBS adds first ustekinumab and omalizumab biosimilars in inflammatory and allergic conditions
From 1 August 2025, two new biosimilars – SteQeyma (ustekinumab) and Omlyclo (omalizumab) – have been listed on the Pharmaceutical […]
More